P. Vermersch Et Al. , "Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)," Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum , vol.26, Florida, United States Of America, pp.32, 2020
Vermersch, P. Et Al. 2020. Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results). Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum , (Florida, United States Of America), 32.
Vermersch, P., Eralinna, J., Nicholas, R., Oreja-Guevara, C., Siva, A., Van Wijmeersch, B., ... Wiendl, H.(2020). Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results) . Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum (pp.32). Florida, United States Of America
Vermersch, P. Et Al. "Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)," Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum, Florida, United States Of America, 2020
Vermersch, P. Et Al. "Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)." Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum , Florida, United States Of America, pp.32, 2020
Vermersch, P. Et Al. (2020) . "Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)." Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum , Florida, United States Of America, p.32.
@conferencepaper{conferencepaper, author={P. Vermersch Et Al. }, title={Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)}, congress name={Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) Forum}, city={Florida}, country={United States Of America}, year={2020}, pages={32} }